3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
12
Neoplasms
8
Prostatic Neoplasms
4
Neoplasm Metastasis
4
Lung Neoplasms
3
Gastrointestinal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Sarcoma
2
Pain
2
Multiple Myeloma
2
Melanoma
2
Hematologic Neoplasms
2
Fatigue
2
Esophageal Neoplasms
2
Carcinoma, Hepatocellular
2
Weight Loss
1
Uterine Cervical Neoplasms
1
To Observe Whether the Fucoidan Can Improve the Quality of Life of the Such Patients Receiving the Neoadjuvant CCRT
1
Thymus Neoplasms
1
Thrombocytopenia
1
Symptom Management
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Splenomegaly
1
Speech
1
Sexual Dysfunction, Physiological
1
Sex Cord-Gonadal Stromal Tumors
1
Sarcoma, Synovial
1
Rectal Neoplasms
1
Interventions
Radiotherapy
6
Doxorubicin
5
Nivolumab
4
pembrolizumab
3
Sunitinib
3
Ifosfamide
3
Gemcitabine
3
Docetaxel
3
pazopanib
2
Radiation Dose Hypofractionation
2
Radiation
2
Methotrexate
2
Ipilimumab
2
Cisplatin
2
CTLA-4 Antigen
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
tremelimumab
1
toripalimab
1
temsirolimus
1
spartalizumab
1
sintilimab
1
ribociclib
1
regorafenib
1
pegfilgrastim
1
liposomal doxorubicin
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
itacitinib
1
fludarabine
1
eribulin
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Histiocytoma, Malignant Fibrous
×
Quality of Life
×
Clear all
NCT07169344
2026-01-28
PROSARC-1
Oslo University Hospital
Phase 2
Recruiting
110 enrolled